Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Shares Outstanding (2016 - 2025)

Sangamo Therapeutics has reported Shares Outstanding over the past 16 years, most recently at $350.7 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $350.7 million for Q4 2025, up 64.77% from a year ago — trailing twelve months through Dec 2025 was $350.7 million (up 64.77% YoY), and the annual figure for FY2025 was $350.7 million, up 64.77%.
  • Shares Outstanding for Q4 2025 was $350.7 million at Sangamo Therapeutics, up from $322.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding for SGMO hit a ceiling of $350.7 million in Q4 2025 and a floor of $143.7 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $177.2 million (2023), compared with a mean of $195.9 million.
  • Biggest five-year swings in Shares Outstanding: increased 2.05% in 2022 and later soared 64.77% in 2025.
  • Sangamo Therapeutics' Shares Outstanding stood at $145.9 million in 2021, then grew by 14.3% to $166.8 million in 2022, then grew by 6.8% to $178.1 million in 2023, then grew by 19.48% to $212.8 million in 2024, then surged by 64.77% to $350.7 million in 2025.
  • The last three reported values for Shares Outstanding were $350.7 million (Q4 2025), $322.0 million (Q3 2025), and $272.8 million (Q2 2025) per Business Quant data.